<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420277</url>
  </required_header>
  <id_info>
    <org_study_id>6090</org_study_id>
    <nct_id>NCT00420277</nct_id>
  </id_info>
  <brief_title>Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty</brief_title>
  <official_title>A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of an Oxygen-Carrying Plasma Expander, Hemospan®, Compared With Voluven® toTreat Hypotension in Patients Undergoing Primary Hip Arthroplasty With Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Hemospan is superior to Voluven for
      treatment of hypotensive episodes during the perioperative period (from induction of spinal
      anesthesia until 6 hours after skin closure), and for reducing the incidence of operative and
      postoperative complications including organ dysfunction and failure until follow-up at one
      month following surgery. An independent Data Safety Monitoring Board (DSMB) will periodically
      evaluate the safety data collected during this trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemospan is a novel hemoglobin-based oxygen carrier developed to perfuse and oxygenate tissue
      at risk for ischemia and hypoxia. As a result of its molecular size and oxygen binding
      characteristics, Hemospan selectively off-loads oxygen in tissues predisposed to low oxygen
      tension. Preclinical evidence suggests that Hemospan provides rapid and effective plasma
      expansion and tissue perfusion, and that the properties of Hemospan target oxygen release in
      the microcirculation.

      Spinal anesthesia is the preferred choice for hip arthroplasty procedures in elderly
      patients, but is associated with a functional hypovolemia due to loss of vascular tone that
      frequently causes acute hypotensive episodes. Hypotension represents a surrogate marker of
      hypovolemia that may be further exacerbated by surgical bleeding, which can result in
      decreased cardiac output, insufficient perfusion and inadequate tissue oxygenation. Ischemia
      resulting from hypotension can adversely affect vital organ function and may result in
      complications and postoperative morbidity. As the population ages and more patients become
      candidates for orthopedic reconstruction or joint replacement surgery, the number of patients
      at risk is increasing. The ideal IV solution for treating hypovolemia-associated hypotension
      and improving hemodynamic stability would be an effective plasma expander that promotes
      tissue perfusion and delivers oxygen to ischemic or marginally hypoxic tissue.

      Preclinical animal studies have shown that Hemospan may be well-suited to this application
      and may even be better than blood in some situations. Data from Sangart's Phase II orthopedic
      surgery study (No. 6055), published recently by Olofsson et al. (Anesthesiology 2006;
      105(6):1153-63) support the safety and potential benefit of Hemospan for preventing and
      treating hypotension in orthopedic surgery patients undergoing hip replacement surgery under
      spinal anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total duration of all hypotensive episodes occurring during anesthesia/surgery and throughout the postoperative period (defined as the first 6 hours following skin closure)</measure>
    <time_frame>Up to 6 hours after skin closure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious operative and postoperative complications, combined into a Composite Morbidity Outcome that includes acute heart failure, acute MI, ischemic stroke, and renal failure</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of operative and postoperative organ dysfunction related to ischemia and/or tissue hypoxia, as a Composite Ischemia Outcome that includes clinical evidence of cerebral ischemia, myocardial ischemia, and renal dysfunction</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (In-hospital, and all-cause at 30 days)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolve/correct the initial hypotensive episode that led to the first dosing trigger</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the second dosing trigger from the first dosing trigger</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients treated successfully with one dose</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypotension</measure>
    <time_frame>Up to 6 hours after skin closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the longest period of hypotension recorded</measure>
    <time_frame>Up to 6 hours after skin closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intervention with a pressor agent to treat hypotensive episodes</measure>
    <time_frame>Up to 6 hours after skin closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative intervention with a diuretic for volume-overload or inadequate urine output</measure>
    <time_frame>Post-operative day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Hypotension</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Hemospan (MP4OX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.3 g/dL MalPEG-Hb solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Voluven (HES 130/0.4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemospan (MP4OX)</intervention_name>
    <description>250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers</description>
    <arm_group_label>Hemospan (MP4OX)</arm_group_label>
    <other_name>MP4OX solution</other_name>
    <other_name>4.3 g/dL MalPEG-Hb</other_name>
    <other_name>PEGylated Hb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voluven (HES 130/0.4)</intervention_name>
    <description>250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>6% HES 130/0.4</other_name>
    <other_name>6% hetastarch solution</other_name>
    <other_name>Voluven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo elective primary hip arthroplasty (based on an
             osteoarthritis diagnosis) under spinal anesthesia

          -  Adult male or female (surgically sterile or post-menopausal), aged 50 years or older

          -  American Society of Anesthesiology (ASA) Class II or III

          -  Physical examination, laboratory status, vital signs, and ECG within acceptable limits
             for the planned surgery, as judged by the investigator

          -  Have been given written and verbal information by the investigator about Hemospan and
             the protocol, and have had the opportunity to ask questions about the study

          -  Patients must sign an Informed Consent form that has been reviewed and approved by the
             independent Ethics Committee

        Exclusion Criteria:

          -  Hip fracture patients and nail/pin extraction procedures

          -  Clinical evidence of uncontrolled cardiovascular, infectious, psychiatric, metabolic
             or systemic disorders including diabetes and rheumatoid arthritis

          -  Evidence of significant hypertension with SBP &gt;180 mmHg, or a difference in SBP
             obtained in each arm that is &gt;15 mmHg (measured in the supine position in both arms,
             at screening)

          -  Recent history or evidence of MI or stroke (within 6 months)

          -  Known alcohol or drug dependency

          -  Currently taking oral anti-coagulant therapy; except for low-dose aspirin
             (acetylsalicylic acid), &lt;200 mg/day

          -  History of coagulopathy

          -  Involved in any investigational drug or device trial within 30 days prior to this
             study

          -  Professional or ancillary personnel involved with this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe van der Linden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann, Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Z.O.L. Genk</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedelijk Ziekenhuis Roeselare</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Motol, I. Ortopedicka klinika</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Motol, II. Ortopedicka klinika</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Na Bulovce</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi Ziekenhuizen, locatie Hilversum</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Maartenskliniek</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Erasmus</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny AM</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP Wojewódzki Szpital Chirurgii Urazowej</name>
      <address>
        <city>Piekary Śląskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny nr 5</name>
      <address>
        <city>Sosnowiec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Reumatologii, Klinika Reumoortopedii</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK Dzieciątka Jezus</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset Gävle</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalmar Hospital</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lasarettet Motala</name>
      <address>
        <city>Motala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyd Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Söder Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Sjukhus</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.sangart.com</url>
    <description>Click here for more information about Sangart, Inc.</description>
  </link>
  <reference>
    <citation>Björkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica. 2005 Apr;90(4):505-15.</citation>
    <PMID>15820947</PMID>
  </reference>
  <reference>
    <citation>Cabrales P, Tsai AG, Winslow RM, Intaglietta M. Effects of extreme hemodilution with hemoglobin-based O2 carriers on microvascular pressure. Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2146-53. Epub 2005 Jan 6.</citation>
    <PMID>15637119</PMID>
  </reference>
  <reference>
    <citation>Young MA, Riddez L, Kjellström BT, Bursell J, Winslow F, Lohman J, Winslow RM. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med. 2005 Aug;33(8):1794-804.</citation>
    <PMID>16096458</PMID>
  </reference>
  <reference>
    <citation>Tsai AG, Cabrales P, Manjula BN, Acharya SA, Winslow RM, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood. 2006 Nov 15;108(10):3603-10. Epub 2006 Jul 20.</citation>
    <PMID>16857991</PMID>
  </reference>
  <reference>
    <citation>Winslow RM. Current status of oxygen carriers ('blood substitutes'): 2006. Vox Sang. 2006 Aug;91(2):102-10. Review.</citation>
    <PMID>16907870</PMID>
  </reference>
  <reference>
    <citation>Olofsson C, Ahl T, Johansson T, Larsson S, Nellgård P, Ponzer S, Fagrell B, Przybelski R, Keipert P, Winslow N, Winslow RM. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology. 2006 Dec;105(6):1153-63.</citation>
    <PMID>17122578</PMID>
  </reference>
  <reference>
    <citation>Winslow RM. Red cell substitutes. Semin Hematol. 2007 Jan;44(1):51-9. Review.</citation>
    <PMID>17198847</PMID>
  </reference>
  <results_reference>
    <citation>van der Linden P, Gazdzik TS, Jahoda D, Heylen RJ, Skowronski JC, Pellar D, Kofranek I, Górecki AZ, Fagrell B, Keipert PE, Hardiman YJ, Levy H; 6090 Study Investigators. A double-blind, randomized, multicenter study of MP4OX for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. Anesth Analg. 2011 Apr;112(4):759-73. doi: 10.1213/ANE.0b013e31820c7b5f. Epub 2011 Feb 11.</citation>
    <PMID>21317165</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Anesthesia, spinal</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Blood substitutes</keyword>
  <keyword>Plasma expanders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

